Literature DB >> 1708755

Trial to induce prostatic cancer in ACI/Seg rats treated with a combination of 3,2'-dimethyl-4-aminobiphenyl and ethinyl estradiol.

K Takai1, T Kakizoe, Y Tanaka, K Tobisu, Y Aso.   

Abstract

In an attempt to induce prostatic adenocarcinoma at higher incidence in a shorter period, we administered diet containing 0.75 ppm of ethinyl estradiol (EE) for three weeks to ACI/Seg rats, which are predisposed to develop a high incidence of microscopic adenocarcinoma of the prostate at higher age. Then, feeding was changed to basal diet and a single subcutaneous injection of 50 mg/kg body weight of 3,2'-dimethyl-4-aminobiphenyl (DMAB) was given two days after the change. We repeated this schedule 10 times. The rats were killed in week 60 of the experiment and subjected to routine autopsy. The average body weight of rats in group 1 given EE and DMAB was lower than that of control rats in group 2. The incidence of adenocarcinoma was not significantly different in the two groups, i.e., 6/74 (8.1%) in group 1 and 2/54 (3.7%) in group 2. The lesions were all microscopic. The incidence of atypical hyperplasia was significantly higher in group 1 at 17 of 74 rats (23.0%) whereas in group 2, it was only 2 of 54 rats (3.7%). Simple hyperplasia was also observed in 25 of 74 rats (33.8%) in group 1, which was significantly higher than that in group 2, where six of 54 rats (11.1%) had this lesion. The reduced growth of animals due to treatments with EE and DMAB probably suppressed the development of prostate cancer in this experiment. Further studies are needed to develop an appropriate model to induce prostate carcinoma at higher incidence in a shorter period.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708755      PMCID: PMC5918399          DOI: 10.1111/j.1349-7006.1991.tb01844.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


N‐nitroso‐N‐methylurea ethinyl estradiol 3,2‐dimethyl‐4‐aminobiphenyl
  16 in total

1.  Prostate carcinogenesis in the AXC rat.

Authors:  S A Shain; B McCullough; M Nitchuk; R W Boesel
Journal:  Oncology       Date:  1977       Impact factor: 2.935

2.  A radioimmunoassay for plasma testosterone.

Authors:  S Furuyama; D M Mayes; C A Nugent
Journal:  Steroids       Date:  1970-10       Impact factor: 2.668

Review 3.  Experimental evidence of dietary factors and hormone-dependent cancers.

Authors:  K K Carroll
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

Review 4.  Prostate carcinoma of the Nb rat in relation to hormones.

Authors:  R L Noble
Journal:  Int Rev Exp Pathol       Date:  1982

5.  Histogenesis and morphology of naturally occurring prostatic carcinoma in the ACI/segHapBR rat.

Authors:  J M Ward; G Reznik; S F Stinson; C P Lattuada; D G Longfellow; T P Cameron
Journal:  Lab Invest       Date:  1980-12       Impact factor: 5.662

6.  Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.

Authors:  M Pollard; P H Luckert
Journal:  J Natl Cancer Inst       Date:  1986-08       Impact factor: 13.506

7.  Induction of prostate carcinoma in situ at high incidence in F344 rats by a combination of 3,2'-dimethyl-4-aminobiphenyl and ethinyl estradiol.

Authors:  T Shirai; S Fukushima; E Ikawa; Y Tagawa; N Ito
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

8.  Sequential changes in the prostate of rats treated with chlormadinone acetate, testosterone and N-nitroso-N-methylurea.

Authors:  K Takai; T Kakizoe; K Tobisu; M Ohtani; K Kishi; S Sato; Y Aso
Journal:  J Urol       Date:  1988-06       Impact factor: 7.450

9.  Metabolic activation of promutagens, detectable in Ames' Salmonella assay, by 5000 X g supernatant of rat ventral prostate.

Authors:  P Söderkvist; L Busk; R Toftgård; J A Gustafsson
Journal:  Chem Biol Interact       Date:  1983-09-01       Impact factor: 5.192

10.  The aging ACI/Seg versus Copenhagen male rat as a model system for the study of prostatic carcinogenesis.

Authors:  J T Isaacs
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.